White Paper

Looking Beyond the Light at the End of the Tunnel

Considerations for post-pandemic management of cardiometabolic clinical trials

Read more

Cardiometabolic clinical research was affected by healthcare directives curtailing outpatient and elective procedures, as well as those encouraging people to stay home whenever possible. In response to these protocols, new guidances emerged from FDA, EMA, and ESC to enable clinical trials to adapt under COVID-19 conditions. The experts at Worldwide Clinical Trials outline operational shifts made in response to the pandemic and predict how they impact the future of cardiovascular studies.


Chief Medical and Scientific Officer
Vice President, General Medicine Medical Lead, Medical Affairs

Want to learn more about Worldwide Clinical Trials?